DNA methylation: its role in transcriptional regulation and association with lung cancer

References

• Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–783.
   PubMed Web of Science ®Google Scholar
• Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10(5):295–304.
   PubMed Web of Science ®Google Scholar
• Du J, Johnson LM, Groth M, et al. Mechanism of DNA methylation-directed histone methylation by KRYPTONITE. Mol Cell. 2014;55(3):495–504.
   Web of Science ®Google Scholar
• Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem. 2003;278(6):4035–4040.
   PubMed Web of Science ®Google Scholar
• Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31(2):89–97.
   PubMed Web of Science ®Google Scholar
• Portela A, Liz J, Nogales V, Setien F, Villanueva A, Esteller M. DNA methylation determines nucleosome occupancy in the 5′-CpG islands of tumor suppressor genes. Oncogene. 2013;32(47):5421–5428.
   Web of Science ®Google Scholar
• Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106(28):11667–11672.
   PubMed Web of Science ®Google Scholar
• Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339–346.
   PubMed Web of Science ®Google Scholar
• Daskalos A, Oleksiewicz U, Filia A, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer. 2011;117(5):1027–1037.
   PubMed Web of Science ®Google Scholar
• Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem. 2011;12(2):206–222.
   PubMed Web of Science ®Google Scholar
• Jeltsch A, Jurkowska RZ. New concepts in DNA methylation. Trends Biochem Sci. 2014;39(7):310–318.
   PubMed Web of Science ®Google Scholar
• Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet. 2009;10(11):805–811.
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930–935.
   PubMed Web of Science ®Google Scholar
• Pham P, Bransteitter R, Petruska J, Goodman MF. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature. 2003;424(6944):103–107.
   PubMed Web of Science ®Google Scholar
• Cannon SV, Cummings A, Teebor GW. 5-Hydroxymethylcytosine DNA glycosylase activity in mammalian tissue. Biochem Biophys Res Commun. 1988;151(3):1173–1179.
   Web of Science ®Google Scholar
• Schmitz KM, Schmitt N, Hoffmann-Rohrer U, Schafer A, Grummt I, Mayer C. TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes leading to active DNA demethylation. Mol Cell. 2009;33(3):344–353.
   PubMed Web of Science ®Google Scholar
• Guo JU, Su Y, Zhong C, Ming GL, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle. 2011;10(16):2662–2668.
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698–711.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89–92.
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–2054.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Rauch TA. DNA methylation patterns in lung carcinomas. Semin Cancer Biol. 2009;19(3):181–187.
   PubMed Web of Science ®Google Scholar
• Gokul G, Khosla S. DNA methylation and cancer. Subcell Biochem. 2013;61:597–625.
   Google Scholar
• Kulis M, Queiros AC, Beekman R, Martin-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta. 2013;1829(11):1161–1174.
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–492.
   PubMed Web of Science ®Google Scholar
• Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet. 2014;30(2):75–84.
   PubMed Web of Science ®Google Scholar
• Blattler A, Farnham PJ. Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem. 2013;288(48):34287–34294.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650–1656.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001.
   PubMed Web of Science ®Google Scholar
• Kanne JP. Screening for lung cancer: what have we learned? Am J Roentgenol. 2014;202(3):530–535.
   PubMed Web of Science ®Google Scholar
• Field JK, van Klaveren R, Pedersen JH, et al; European Randomized Screening Trial Group. European randomized lung cancer screening trials: post NLST. J Surg Oncol. 2013;108(5):280–286.
   PubMed Web of Science ®Google Scholar
• Bediaga NG, Davies MP, Acha-Sagredo A, et al. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br J Cancer. 2013;109(9):2404–2411.
   Web of Science ®Google Scholar
• Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6:518.
   PubMedGoogle Scholar
• Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer. 2010;10:600.
   PubMed Web of Science ®Google Scholar
• Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. Cancer Biomark. 2014;14(4):207–214.
   Web of Science ®Google Scholar
• Nie FQ, Zhu Q, Xu TP, et al. Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. Tumour Biol. 2014;35(8):7587–7594.
   PubMedGoogle Scholar
• Zhang H, Liu J, Yue D, Gao L, Wang D, Wang C. Clinical significance of E-cadherin, beta-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 2013;66(11):937–945.
   Web of Science ®Google Scholar
• El-Chaar NN, Piccolo SR, Boucher KM, et al. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol. 2014;8(7):1339–1354.
   Web of Science ®Google Scholar
• Feng JF, Wu JZ, Hu SN, et al. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer. 2009;66(3):344–349.
   Web of Science ®Google Scholar
• Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014;15(7):713–721.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Schache AG, Hall G, Woolgar JA, et al. Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer. 2010;103(12):1846–1851.
   PubMed Web of Science ®Google Scholar
• Sandoval J, Peiro-Chova L, Pallardo FV, Garcia-Gimenez JL. Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities. Expert Rev Mol Diagn. 2013;13(5):457–471.
   PubMed Web of Science ®Google Scholar
• Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014;4:204.
   PubMedGoogle Scholar
• Liloglou T, Field JK. Detection of DNA methylation changes in body fluids. Adv Genet. 2010;71:177–207.
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286–298.
   PubMed Web of Science ®Google Scholar
• Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342(2):200–212.
   PubMed Web of Science ®Google Scholar
• Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003;22(23):6335–6345.
   Web of Science ®Google Scholar
• Hughes S, Jones JL. The use of multiple displacement amplified DNA as a control for methylation specific PCR, pyrosequencing, bisulfite sequencing and methylation-sensitive restriction enzyme PCR. BMC Mol Biol. 2007;8:91.
   PubMed Web of Science ®Google Scholar
• Schumacher A, Weinhausl A, Petronis A. Application of microarrays for DNA methylation profiling. Methods Mol Biol. 2008;439:109–129.
   PubMedGoogle Scholar
• Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–9826.
   PubMed Web of Science ®Google Scholar
• Krueger F, Kreck B, Franke A, Andrews SR. DNA methylome analysis using short bisulfite sequencing data. Nat Methods. 2012;9(2):145–151.
   PubMed Web of Science ®Google Scholar
• Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer. 2009;124(1):81–87.
   PubMed Web of Science ®Google Scholar
• Ehrich M, Field JK, Liloglou T, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res. 2006;66(22):10911–10918.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques. 2002;33(3):632,634. 636–649.
   Web of Science ®Google Scholar
• Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem. 2009;55(8):1471–1483.
   PubMed Web of Science ®Google Scholar
• Wojdacz TK, Hansen LL, Dobrovic A. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes. 2008;1:54.
   PubMedGoogle Scholar
• Nikolaidis G, Raji OY, Markopoulou S, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012;72(22):5692–5701.
   PubMed Web of Science ®Google Scholar
• Hernandez HG, Tse MY, Pang SC, Arboleda H, Forero DA. Optimizing methodologies for PCR-based DNA methylation analysis. Biotechniques. 2013;55(4):181–197.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15(11):3881–3888.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Liloglou T, Rogers SN, et al. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer. 2006;94(4):561–568.
   PubMed Web of Science ®Google Scholar
• Fackler MJ, Rivers A, Teo WW, et al. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res. 2009;15(11):3802–3811.
   Web of Science ®Google Scholar
• Vaissiere T, Cuenin C, Paliwal A, et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics. 2009;4(4):221–230.
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Dietrich D, Liebenberg V, Field JK, Schmidt B. The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev Respir Med. 2013;7(4):363–383.
   PubMed Web of Science ®Google Scholar
• Nelson HH, Marsit CJ, Christensen BC, et al. Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics. 2012;7(6):559–566.
   PubMed Web of Science ®Google Scholar
• Do H, Wong NC, Murone C, et al. A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Sci Rep. 2014;4:4186.
   Web of Science ®Google Scholar
• Tammemagi MC, Lam S. Screening for lung cancer using low dose computed tomography. BMJ. 2014;348:g2253.
   Google Scholar
• Zhao Y, Zhou H, Ma K, et al. Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. Oncol Lett. 2013;5(4):1211–1218.
   PubMed Web of Science ®Google Scholar
• Geng J, Sun J, Lin Q, et al. Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol Lett. 2012;3(4):901–906.
   Web of Science ®Google Scholar
• Heller G, Weinzierl M, Noll C, et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res. 2012;18(6):1619–1629.
   PubMed Web of Science ®Google Scholar
• Hua F, Fang N, Li X, Zhu S, Zhang W, Gu J. A meta-analysis of the relationship between RARbeta gene promoter methylation and non-small cell lung cancer. PLoS One. 2014;9(5):e96163.
   Web of Science ®Google Scholar
• Gu J, Wen Y, Zhu S, et al. Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One. 2013;8(4):e60107.
   Web of Science ®Google Scholar
• Guo S, Tan L, Pu W, et al. Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epigenetics. 2014;6(1):5.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546.
   PubMed Web of Science ®Google Scholar
• Bradly DP, Gattuso P, Pool M, et al. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012;21(4):207–213.
   PubMedGoogle Scholar
• Harada H, Miyamoto K, Yamashita Y, et al. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer. 2013;119(4):792–798.
   Web of Science ®Google Scholar
• Heller G, Babinsky VN, Ziegler B, et al. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis. 2013;34(3):513–521.
   PubMed Web of Science ®Google Scholar
• Koga T, Takeshita M, Ijichi K, Yano T, Maehara Y, Sueishi K. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes. Hum Pathol. 2013;44(7):1382–1390.
   Web of Science ®Google Scholar
• Wu D, Xiong L, Wu S, Jiang M, Lian G, Wang M. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;76(1):106–111.
   Web of Science ®Google Scholar
• Nadal E, Chen G, Gallegos M, et al. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19(24):6842–6852.
   Web of Science ®Google Scholar
• Cao J, Song Y, Bi N, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013;73(11):3326–3335.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21(2):93–104.
   PubMedGoogle Scholar
• Na Y, Lee SM, Kim DS, Park JY. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers. Cancer Biomark. 2012;12(2):73–79.
   Web of Science ®Google Scholar
• Ramnath N, Nadal E, Jeon CK, et al. Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma. J Thorac Oncol. 2014;9(4):473–482.
   Web of Science ®Google Scholar
• Lokk K, Vooder T, Kolde R, et al. Methylation markers of early-stage non-small cell lung cancer. PLoS One. 2012;7(6):e39813.
   PubMed Web of Science ®Google Scholar
• de Fraipont F, Levallet G, Creveuil C, et al; Intergroupe Francophone de Cancérologie Thoracique. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res. 2012;18(10):2976–2986.
   Google Scholar
• Ko E, Lee BB, Kim Y, et al. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clin Cancer Res. 2013;19(5):1204–1212.
   Web of Science ®Google Scholar
• Lee SM, Lee WK, Kim DS, Park JY. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance. Mol Med Rep. 2012;5(1):239–244.
   Web of Science ®Google Scholar
• Morán A, Fernández-Marcelo T, Carro J, et al. Methylation profiling in non-small cell lung cancer: clinical implications. Int J Oncol. 2012;40(3):739–746.
   PubMed Web of Science ®Google Scholar
• Cortés-Sempere M, de Miguel MP, Pernía O, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene. 2013;32(10):1274–1283.
   Web of Science ®Google Scholar
• Zhu J, Wang Y, Duan J, et al. DNA methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2012;31:80.
   PubMed Web of Science ®Google Scholar
• Li N, Zhang F, Li S, Zhou S. Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun. 2014;444(4):611–616.
   PubMed Web of Science ®Google Scholar
• Hochhauser D, Glynne-Jones R, Potter V, et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013;12(5):809–818.
   PubMed Web of Science ®Google Scholar
• Dobler CC, Crawford AB. Bronchoscopic diagnosis of endoscopically visible lung malignancies: should cytological examinations be carried out routinely? Intern Med J. 2009;39(12):806–811.
   Web of Science ®Google Scholar
• Van’t Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. Cancer J. 2011;17(1):3–10.
   Web of Science ®Google Scholar
• Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst. 1999;91(4):332–339.
   PubMed Web of Science ®Google Scholar
• van der Drift MA, Prinsen CF, Knuiman GJ, Janssen JP, Dekhuijzen PN, Thunnissen FB. Diagnosing peripheral lung cancer: the additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy. Chest. 2012;141(1):169–175.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Kneip C, Raji O, et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol. 2012;40(3):825–832.
   PubMed Web of Science ®Google Scholar
• Darwiche K, Zarogoulidis P, Baehner K, et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol. 2013;24(11):2866–2870.
   PubMed Web of Science ®Google Scholar
• Hubers AJ, van der Drift MA, Prinsen CF, et al. Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer. 2014;84(2):127–133.
   Web of Science ®Google Scholar
• Leng S, Do K, Yingling CM, et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res. 2012;18(12):3387–3395.
   PubMed Web of Science ®Google Scholar
• Powrozek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917.
   PubMed Web of Science ®Google Scholar
• Balgkouranidou I, Chimonidou M, Milaki G, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer. 2014;110(8):2054–2062.
   PubMed Web of Science ®Google Scholar
• Li W, Deng J, Jiang P, Zeng X, Hu S, Tang J. Methylation of the RASSF1A and RARbeta genes as a candidate biomarker for lung cancer. Exp Ther Med. 2012;3(6):1067–1071.
   Web of Science ®Google Scholar
• Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer. 2013;81(3):397–403.
   PubMed Web of Science ®Google Scholar
• Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011;6(10):1632–1638.
   PubMed Web of Science ®Google Scholar
• Ilse P, Biesterfeld S, Pomjanski N, Fink C, Schramm M. SHOX2 DNA methylation is a tumour marker in pleural effusions. Cancer Genomics Proteomics. 2013;10(5):217–223.
   PubMed Web of Science ®Google Scholar
• Bruno P, Gentile G, Mancini R, et al. WT1 CpG islands methylation in human lung cancer: a pilot study. Biochem Biophys Res Commun. 2012;426(3):306–309.
   Web of Science ®Google Scholar
• Carvalho RH, Haberle V, Hou J, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin. 2012;5(1):9.
   PubMedGoogle Scholar
• Huang T, Jiang M, Kong X, Cai YD. Dysfunctions associated with methylation, microRNA expression and gene expression in lung cancer. PLoS One. 2012;7(8):e43441.
   Web of Science ®Google Scholar
• Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol. 2013;230(2):194–204.
   PubMed Web of Science ®Google Scholar
• Lee SM, Park JY, Kim DS. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer. Mol Cells. 2012;34(2):171–176.
   PubMed Web of Science ®Google Scholar
• Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells. 2013;36(1):69–73.
   Web of Science ®Google Scholar
• Li B, Lu Q, Song ZG, et al. Functional analysis of DNA methylation in lung cancer. Eur Rev Med Pharmacol Sci. 2013;17(9):1191–1197.
   Web of Science ®Google Scholar
• Liu WB, Han F, Jiang X, et al. ANKRD18A as a novel epigenetic regulation gene in lung cancer. Biochem Biophys Res Commun. 2012;429(3–4):180–185.
   Web of Science ®Google Scholar
• Liu WB, Han F, Jiang X, et al. Epigenetic regulation of ANKRD18B in lung cancer. Mol Carcinog. Epub November 19, 2013.
   Google Scholar
• Liu WB, Han F, Du XH, et al. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer. Int J Cancer. 2014;134(6):1311–1322.
   Web of Science ®Google Scholar
• Liu WB, Jiang X, Han F, et al. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer. Cell Death Dis. 2013;4:e882.
   Web of Science ®Google Scholar
• Lu KH, Li W, Liu XH, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013;13:461.
   PubMed Web of Science ®Google Scholar
• Meng W, Ye Z, Cui R, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 2013;19(19):5423–5433.
   PubMed Web of Science ®Google Scholar
• Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 2013;31(32):4140–4147.
   PubMed Web of Science ®Google Scholar
• Sato T, Arai E, Kohno T, et al. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One. 2013;8(3):e59444.
   Web of Science ®Google Scholar
• Sato T, Arai E, Kohno T, et al. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer. 2014;135(2):319–334.
   PubMed Web of Science ®Google Scholar
• Scesnaite A, Jarmalaite S, Mutanen P, et al. Similar DNA methylation pattern in lung tumours from smokers and never-smokers with second-hand tobacco smoke exposure. Mutagenesis. 2012;27(4):423–429.
   Web of Science ®Google Scholar
• Shi J, Marconett CN, Duan J, et al. Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. Nat Commun. 2014;5:3365.
   PubMed Web of Science ®Google Scholar
• Shinjo K, Okamoto Y, An B, et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis. 2012;33(7):1277–1285.
   PubMed Web of Science ®Google Scholar
• Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197–1211.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Shiraishi K, Eguchi A, et al. Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol Rep. 2013;29(4):1308–1314.
   Web of Science ®Google Scholar
• Tan SX, Hu RC, Tan YL, Liu JJ, Liu WE. Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma. Tumour Biol. 2014;35(5):4509–4516.
   PubMedGoogle Scholar
• Tang X, Yin X, Xiang T, et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark. 2012;12(1):11–19.
   Web of Science ®Google Scholar
• Tekpli X, Zienolddiny S, Skaug V, Stangeland L, Haugen A, Mollerup S. DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int J Cancer. 2012;131(7):1509–1516.
   PubMed Web of Science ®Google Scholar
• Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One. 2012;7(3):e32921.
   Web of Science ®Google Scholar
• Tessema M, Yingling CM, Grimes MJ, et al. Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS One. 2012;7(4):e34850.
   Web of Science ®Google Scholar
• Walter K, Holcomb T, Januario T, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res. 2012;18(8):2360–2373.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Yin X, Walter V, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012;7(5):e36530.
   PubMed Web of Science ®Google Scholar
• Yin D, Jia Y, Yu Y, et al. SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov Med. 2012;14(74):33–40.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang N, Zhang M, Xue S, Shi K, Chen Z. Detection of methylation of the RAR-beta gene in patients with non-small cell lung cancer. Oncol Lett. 2012;3(3):654–658.
   Web of Science ®Google Scholar
• Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene. 2013;32(30):3559–3568.
   Web of Science ®Google Scholar
• Tanaka N, Toyooka S, Soh J, et al. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer. 2012;76(1):32–38.
   PubMed Web of Science ®Google Scholar
• Shin KC, Lee KH, Lee CH, Shin IH, Suh HS, Jeon CH. MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases. Oncol Rep. 2012;27(4):911–916.
   Web of Science ®Google Scholar
• Tan S, Sun C, Wei X, et al. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood. Exp Lung Res. 2013;39(4–5):182–190.
   PubMed Web of Science ®Google Scholar
• Kontic M, Stojsic J, Jovanovic D, et al. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer. 2012;13(4):297–303.
   PubMed Web of Science ®Google Scholar